XML 46 R12.htm IDEA: XBRL DOCUMENT v3.22.0.1

SPECIAL CHARGES	12 Months Ended
	Dec. 31, 2021
Other Income and Expenses [Abstract]
SPECIAL CHARGES	SPECIAL CHARGES Impairment of Long-lived Assets In December 2019, the Company recorded a charge of $40.6 million to fully impair certain in-process research and development assets. These assets were acquired as part of the acquisition of Valtech Cardio Ltd. ("Valtech") in 2017. The Company measured the amount of the impairment by calculating the amount by which the carrying values exceeded the estimated fair values, which was based on projected discounted future net cash flows. Based on market and clinical trial developments at the time of the impairment, the Company re-evaluated the clinical development plans for the technologies acquired from Valtech, which resulted in a reduction to the projected near-term discounted future net cash flows related to the acquired mitral and tricuspid technology. The impairment was recorded to the Company’s Rest of World segment. Acquisition of Intellectual Property In March 2019, the Company recorded a $24.0 million charge related to the acquisition of early-stage transcatheter intellectual property and associated clinical and regulatory experience.

X

- References

No definition available.

+ Details

Name:	us-gaap_OtherIncomeAndExpensesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure for an event or transaction that is unusual in nature or infrequent in occurrence, or both.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 20
-URI http://asc.fasb.org/subtopic&trid=114868817

+ Details

Name:	us-gaap_UnusualOrInfrequentItemsDisclosureTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration